Sinocelltech Group Ltd

Sinocelltech's controlling subsidiary has received clinical trial approval from the National Medical Products Administration for its independently developed SCTA02A injection, which will be used in a clinical trial for chronic hepatitis B. This product is the first approved clinical candidate in the company's portfolio designed with the goal of achieving a functional cure for chronic hepatitis B. In the first quarter of 2026, Sinocelltech reported revenue of 323 million yuan and a net loss attributable to the parent company of 176 million yuan.

Sinocelltech's controlling subsidiary, Sinocelltech Engineering, has received a drug clinical trial approval notice issued by the National Medical Products Administration, approving the SCTB10 injection to begin clinical trials for hemophilia A. SCTB10 is a recombinant anti-FIXa/FX bispecific antibody injection independently developed by the company. It works by binding activated FIXa and FX to mimic the procoagulant function of coagulation factor VIII, replacing the missing factor VIII to restore coagulation function. The optimized SCTB10 is expected to replace traditional intravenous infusion with subcutaneous injection, significantly reducing dosing frequency and achieving better prophylactic treatment outcomes. This clinical trial will evaluate the safety, tolerability, pharmacokinetics, and efficacy of SCTB10 in patients with hemophilia A.